3CPM

Executive Summary

3CPM is a Boston-based private company specializing in a non-invasive electrogastrography (EGG) test for diagnosing gastrointestinal motility disorders, including gastroparesis and functional dyspepsia. The company claims its AI-derived patented technology achieves 100% sensitivity and selectivity, offering a simple 45-minute test that can subtype disease to optimize treatment. Founded in 2003, 3CPM markets itself as the only approved test for accurately characterizing these conditions. With no disclosed funding or valuation, the company operates in the clinical research and digital health categories, focusing on personalized diagnosis and therapy. Despite its long history, 3CPM remains private and has limited public information, suggesting a niche but potentially impactful position in gastroenterology diagnostics. Its value proposition centers on replacing invasive procedures with a quick, accurate, and AI-enhanced alternative, which could drive adoption if clinical evidence and regulatory endorsements continue to support its claims.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical trial results in peer-reviewed journal70% success
• Q2 2027Strategic partnership with major gastroenterology clinic or hospital network50% success
• TBDExpansion of FDA labeling to include additional GI motility indications40% success